MedTrace Logo

LINQ for impEdance meAsuremeNt While Off From HF Medication Study

NCT03245281 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-06-21

No results posted yet for this study

Summary

The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in patients with heart failure during periods when diuretics and/or HF-medication consumption is increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect safety information related to HF status and to medication consumption changes.

Conditions

Interventions

DRUG

Diuretic Suspension (DS)

Stop diuretic consumption in the 48h before the follow-up visit

DRUG

Diuretic Increase (DI)

Double diuretics dosage in the 48h before the follow-up visit

DRUG

Diuretic and Medication Suspension (DMS)

Stop diuretic and MRA medication consumption in the 48h before the follow-up visit

Sponsors & Collaborators

  • Medtronic BRC

    lead INDUSTRY

Principal Investigators

  • John Cleland, Prof · NHS Greater Glasgow & Clyde

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2019-01-31
Completion
2019-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245281 on ClinicalTrials.gov